May 14, 2012

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Sponsors and Collaborators

Novartis Pharmaceuticals

Contact

Novartis Pharmaceuticals

ClinicalTrials.gov Identifier

Topics:

Renal Cell Carcinoma

Next post in Renal Cell Carcinoma

The new risk score, developed by Emory researchers, could be a useful tool for determining overall and progression-free survival after immunotherapy.

Factors Associated With Response to Nivolumab in Renal Cell Carcinoma